Bipolar Disorder Clinical Trials in New York

Showing 81-87 of 87 trials

Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

NCT00322764

The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.

Bipolar Depression

Repligen Corporation80 participantsStarted Mar 2006

Stanford, California, United States • Smyrna, Georgia, United States • Indianapolis, Indiana, United States +8 more locations

UNKNOWNPhase 3< 1 mile

Safety and Efficacy Study of Lithium in Bipolar Disorder

NCT00422331

The purpose of this study is to determine whether Lithium is safe and effective in the treatment of Bipolar I Disorder subjects with symptoms of acute mania.

Bipolar DisorderMania

JDS Pharmaceuticals206 participantsStarted Jan 2007

New York, New York, United States

TERMINATEDPhase 4< 1 mile

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

NCT00071253

The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs. Depakote monotherapy and olanzapine monotherapy in stable subjects during the maintenance phase of bipolar illness.

Bipolar Disorder

Abbott180 participantsStarted Jul 2003

Anaheim, California, United States • Chula Vista, California, United States • Fort Meyers, Florida, United States +12 more locations

Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

Safety and Efficacy Study of Lithium in Bipolar Disorder

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Bipolar Disorder Trials in Other Cities

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

Other Conditions in New York